Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland
Advertisement

Tripep shares plummet as HIV drug disappoints

Share this article

18:10 CEST+02:00
Shares in Swedish biotech company Tripep AB crash dived after the company said it will probably scrap its alphaHGA HIV-inhibiting drug after trials in Thailand showed "no significant decrease of the HIV-levels in the patients' serum".

At 1.20 pm Tripep was down 65% at 4.62 kronor, while the OMX Stockholm was down 0.53% at 342.90.

"Naturally we are very disappointed," said Tripep. "A study report will be prepared but right now it is hard to see a continuation of the alphaHGA project".

Tripep's share price went vertical in January, reaching a high of 17.90 kronor amid optimism surrounding the trials in Thailand.

Tripep said it will now focus its research and resources on Hepatitis C.

AFX

Get notified about breaking news on The Local

Share this article

Advertisement

From our sponsors

'Lagom' leadership: the secret to Swedish success?

Is the Swedish approach to leadership really as special as people think? The Local asks a non-Swedish manager at telecom giant Ericsson for a frank appraisal of Swedes' so-called 'lagom' leadership style.

Advertisement
Advertisement
Jobs
Click here to start your job search
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement